Stock Quote Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lianbio ADR (NQ: LIAN ) 1.740 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 1.740 Bid (Size) 1.500 (2) Ask (Size) 1.860 (11) Prev. Close 1.740 Today's Range 1.740 - 1.740 52wk Range 1.070 - 6.240 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year Top News More News 12 Health Care Stocks Moving In Tuesday's After-Market Session February 21, 2023 Via Benzinga Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 12, 2023 Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity... Via Benzinga Performance YTD +10.83% +10.83% 1 Month -18.12% -18.12% 3 Month +4.19% +4.19% 6 Month -21.27% -21.27% 1 Year -40.41% -40.41% More News Read More Pfizer Opts In To LianBio Rights to Respiratory Syncytial Virus Candidate In Greater China December 19, 2022 Via Benzinga LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial October 13, 2022 Via Benzinga LinkDoc Formally Withdraws Its U.S. IPO. Next Stop, Hong Kong? April 18, 2022 Via Benzinga Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore December 19, 2022 From LianBio; Pfizer Inc. Via Globe NewsWire LianBio Announces President and Chief Strategy Officer Departure December 13, 2022 From LianBio Via Globe NewsWire LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 10, 2022 From LianBio Via Globe NewsWire LianBio to Participate in Upcoming Investor and Industry Events November 10, 2022 From LianBio Via Globe NewsWire LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors November 09, 2022 From LianBio Via Globe NewsWire LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis November 01, 2022 From LianBio Via Globe NewsWire NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer September 07, 2022 From NANOBIOTIX Via Business Wire Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal August 13, 2022 Via Talk Markets Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary August 10, 2022 Via Benzinga 4 Stocks Under $4 Insiders Are Aggressively Buying May 31, 2022 Via Benzinga Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company April 30, 2022 Via Talk Markets Mid-Afternoon Market Update: Nasdaq Down 3%; Accolade Shares Slide April 29, 2022 Via Benzinga 70 Biggest Movers From Friday May 02, 2022 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session April 29, 2022 Via Benzinga Mid-Day Market Update: Dow Dips 500 Points; GTY Technology Holdings Shares Jump April 29, 2022 Via Benzinga 48 Stocks Moving In Friday's Mid-Day Session April 29, 2022 Via Benzinga Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points April 29, 2022 Via Benzinga 68 Biggest Movers From Yesterday April 05, 2022 Via Benzinga U.S.-Bound China IPO Train Could Resume by Summer, Latest Signals Show April 04, 2022 Via Benzinga 35 Stocks Moving In Monday's Mid-Day Session April 04, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
